Biotech Values

[dewophile]

I found this summary of the older adult rsv vaccine landscape. It's a quick comparison of top line data that we have to date, and the other players who are expecting data soon. It's superficial and omits some important details (and obviously a lot of data is still not public), but still a nice succinct overview of where things stand today

https://www.evaluate.com/vantage/articles/news/trial-results-snippets/moderna-looks-spoil-gsk-and-pfizers-respiratory